You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHaloperidol
Accession NumberDB00502  (APRD00538)
TypeSmall Molecule
GroupsApproved
DescriptionA phenyl-piperidinyl-butyrophenone that is used primarily to treat schizophrenia and other psychoses. It is also used in schizoaffective disorder, delusional disorders, ballism, and tourette syndrome (a drug of choice) and occasionally as adjunctive therapy in mental retardation and the chorea of huntington disease. It is a potent antiemetic and is used in the treatment of intractable hiccups. (From AMA Drug Evaluations Annual, 1994, p279)
Structure
Thumb
Synonyms
1-(3-P-Fluorobenzoylpropyl)-4-P-chlorophenyl-4-hydroxypiperidine
4-(4-(Para-chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one
4'-Fluoro-4-(4-(P-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone
4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone
gamma-(4-(P-Chlorophenyl)-4-hydroxpiperidino)-P-fluorbutyrophenone
Haldol
Haloperidolum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Haldolinjection5 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1971-05-18Not applicableUs
Haldol Decanoateinjection50 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs
Haldol Decanoateinjection100 mg/mLintramuscularJanssen Pharmaceuticals, Inc.1986-01-14Not applicableUs
Haldol Injection 5mg/mlliquid5 mgintramuscularMcneil Pharmaceutical, Division Of Ortho Mcneil Inc.1966-12-312006-08-04Canada
Haldol LA Inj 100mg/mlliquid100 mgintramuscularJanssen Inc1983-12-312006-08-04Canada
Haldol LA Inj 50mg/mlliquid50 mgintramuscularJanssen Inc1983-12-312006-01-23Canada
Haloperidolinjection5 mg/mLintramuscularTYA Pharmaceuticals2011-06-17Not applicableUs
Haloperidolinjection5 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-29Not applicableUs
Haloperidolinjection5 mg/1intramuscularREMEDYREPACK INC.2013-04-10Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularPatriot Pharmaceuticals LLC2011-06-17Not applicableUs
Haloperidol Decanoate Inj. Liq Im 100mg/mlliquid100 mgintramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Haloperidol Decanoate Inj. Liq Im 50mg/mlliquid50 mgintramuscularDavid Bull Laboratories (Pty) Ltd.1995-12-311998-08-13Canada
Haloperidol Decanoate Injectionsolution100 mgintramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Haloperidol Decanoate Injectionliquid100 mgintramuscularHospira Healthcare CorporationNot applicableNot applicableCanada
Haloperidol Decanoate Injectionsolution50 mgintramuscularMylan Pharmaceuticals UlcNot applicableNot applicableCanada
Haloperidol Decanoate Injectionliquid50 mgintramuscularHospira Healthcare CorporationNot applicableNot applicableCanada
Haloperidol Inj 5mg/ml USPliquid5 mgintramuscularSandoz Canada Incorporated1989-12-31Not applicableCanada
Haloperidol Injectionsolution5 mgintramuscularOmega Laboratories Ltd2011-09-19Not applicableCanada
Haloperidol Injection, USPsolution5 mgintramuscularFresenius Kabi Canada Ltd2014-10-20Not applicableCanada
Haloperidol LAliquid50 mgintramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada
Haloperidol LAliquid100 mgintramuscularSandoz Canada Incorporated1994-12-31Not applicableCanada
Haloperidol Long Actingliquid50 mgintramuscularNovopharm Limited2001-08-022005-08-10Canada
Haloperidol Long Actingliquid100 mgintramuscularNovopharm Limited2001-08-022005-08-10Canada
Haloperidol Tab 0.5mgtablet.5 mgoralPro Doc Limitee1983-12-312010-07-13Canada
Haloperidol Tab 1mgtablet1 mgoralPro Doc Limitee1983-12-312010-07-13Canada
Haloperidol Tab 2mgtablet2 mgoralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol Tab 5mgtablet5 mgoralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol-10 Tab 10mgtablet10 mgoralPro Doc Limitee1988-12-312010-07-13Canada
Haloperidol-LA Omegaliquid100 mgintramuscularOmega Laboratories Ltd1999-05-28Not applicableCanada
Haloperidol-LA Omegaliquid50 mgintramuscularOmega Laboratories Ltd1999-06-30Not applicableCanada
Novo-peridoltablet10 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Novo-peridoltablet0.5 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Novo-peridoltablet20 mgoralTeva Canada Limited1988-12-31Not applicableCanada
Novo-peridoltablet1 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Novo-peridoltablet5 mgoralTeva Canada Limited1984-12-31Not applicableCanada
Novo-peridoltablet2 mgoralTeva Canada Limited1986-12-31Not applicableCanada
Novo-peridol Oral Soln 2mg/mlsolution2 mgoralNovopharm Limited1987-12-312005-08-10Canada
Nu-haloperidoltablet5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidoltablet0.5 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidoltablet10 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidoltablet1 mgoralNu Pharm IncNot applicableNot applicableCanada
Nu-haloperidoltablet2 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-haloperidol Soln 2mg/mlsolution2 mgoralPharmascience Inc1988-12-31Not applicableCanada
PMS-haloperidol-LAliquid50 mgintramuscularPharmascience Inc1997-09-24Not applicableCanada
PMS-haloperidol-LAliquid100 mgintramuscularPharmascience Inc1997-08-17Not applicableCanada
Ratio-haloperidol 2mg/mlsolution2 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 0.5mgtablet.5 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 10mgtablet10 mgoralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada
Ratio-haloperidol Tab 1mgtablet1 mgoralRatiopharm Inc Division Of Teva Canada Limited1982-12-312006-08-04Canada
Ratio-haloperidol Tab 2mgtablet2 mgoralRatiopharm Inc Division Of Teva Canada Limited1987-12-312006-08-04Canada
Ratio-haloperidol Tab 5mgtablet5 mgoralRatiopharm Inc Division Of Teva Canada Limited1985-12-312006-08-04Canada
Rho-haloperidol Decanoate Inj.-im 100mg/mlsolution100 mgintramuscularRhodiapharm Inc1997-05-072005-08-01Canada
Rho-haloperidol Decanoate Inj.-im 50mg/mlsolution50 mgintramuscularRhodiapharm Inc1997-05-072005-08-01Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Haloperidol Liq 2mg/mlliquid2 mgoralApotex Inc1983-12-31Not applicableCanada
Apo Haloperidol Tab 0.5mgtablet.5 mgoralApotex Inc1980-12-31Not applicableCanada
Apo Haloperidol Tab 1mgtablet1 mgoralApotex Inc1980-12-31Not applicableCanada
Apo-haloperidol LA Injectableliquid100 mgintramuscularApotex Inc2000-06-302013-08-02Canada
Apo-haloperidol LA Injectableliquid50 mgintramuscularApotex Inc2000-06-302013-08-02Canada
Apo-haloperidol Tab 10mgtablet10 mgoralApotex Inc1987-12-31Not applicableCanada
Apo-haloperidol Tab 2mgtablet2 mgoralApotex Inc1987-12-31Not applicableCanada
Apo-haloperidol Tab 5mgtablet5 mgoralApotex Inc1987-12-31Not applicableCanada
Haloperidoltablet10 mg/1oralREMEDYREPACK INC.2011-09-15Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularCardinal Health2011-05-10Not applicableUs
Haloperidoltablet20 mg/1oralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs
Haloperidoltablet2 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs
Haloperidoltablet1 mg/1oralSandoz Inc1986-11-17Not applicableUs
Haloperidoltablet10 mg/1oralMajor Pharmaceuticals2015-03-25Not applicableUs
Haloperidoltablet20 mg/1oralREMEDYREPACK INC.2013-02-19Not applicableUs
Haloperidoltablet10 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularPfizer Laboratories Div Pfizer Inc2011-05-10Not applicableUs
Haloperidoltablet.5 mg/1oralCardinal Health2012-09-05Not applicableUs
Haloperidoltablet2 mg/1oralTYA Pharmaceuticals1986-06-10Not applicableUs
Haloperidoltablet5 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
Haloperidoltablet.5 mg/1oralMylan Institutional Inc.2004-02-01Not applicableUs
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Haloperidoltablet5 mg/1oralCardinal Health1986-11-17Not applicableUs
Haloperidoltablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
Haloperidoltablet20 mg/1oralSandoz Inc1988-03-11Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularSagent Pharmaceuticals2011-10-24Not applicableUs
Haloperidolinjection5 mg/mLintramuscularGeneral Injectables and Vaccines, Inc2014-09-29Not applicableUs
Haloperidoltablet.5 mg/1oralPhysicians Total Care, Inc.1999-04-29Not applicableUs
Haloperidoltablet1 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
Haloperidoltablet1 mg/1oralLake Erie Medical DBA Quality Care Products LLC1986-11-17Not applicableUs
Haloperidolinjection5 mg/mLintramuscularTeva Parenteral Medicines, Inc.2002-03-01Not applicableUs
Haloperidoltablet10 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2011-10-21Not applicableUs
Haloperidoltablet5 mg/1oralCardinal Health2004-02-15Not applicableUs
Haloperidoltablet.5 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
Haloperidoltablet5 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs
Haloperidoltablet2 mg/1oralSandoz Inc1986-11-17Not applicableUs
Haloperidoltablet5 mg/1oralRebel Distributors Corp1986-11-17Not applicableUs
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2013-07-01Not applicableUs
Haloperidolsolution2 mg/mLoralSilarx Pharmaceuticals, Inc2009-09-08Not applicableUs
Haloperidolsolution, concentrate2 mg/mLoralTeva Pharmaceuticals USA Inc1988-12-01Not applicableUs
Haloperidoltablet5 mg/1oralCardinal Health1986-06-10Not applicableUs
Haloperidoltablet5 mg/1oralTYA Pharmaceuticals1986-06-10Not applicableUs
Haloperidoltablet10 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
Haloperidoltablet1 mg/1oralMylan Institutional Inc.2004-02-01Not applicableUs
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Haloperidoltablet2 mg/1oralCardinal Health1986-11-17Not applicableUs
Haloperidoltablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
Haloperidoltablet1 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs
Haloperidoltablet10 mg/1oralAmerican Health Packaging2008-03-04Not applicableUs
Haloperidoltablet5 mg/1oralAmerican Health Packaging2016-02-08Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularSagent Pharmaceuticals2011-10-24Not applicableUs
Haloperidolinjection5 mg/mLintramuscularCardinal Health2001-06-19Not applicableUs
Haloperidoltablet5 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
Haloperidoltablet.5 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs
Haloperidolinjection5 mg/mLintramuscularTeva Parenteral Medicines, Inc.2002-03-01Not applicableUs
Haloperidoltablet20 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularREMEDYREPACK INC.2013-06-13Not applicableUs
Haloperidoltablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Haloperidoltablet.5 mg/1oralCardinal Health1986-11-17Not applicableUs
Haloperidolsolution2 mg/mLoralQualitest Pharmaceuticals1993-09-28Not applicableUs
Haloperidoltablet10 mg/1oralClinical Solutions Wholesale1988-03-11Not applicableUs
Haloperidoltablet5 mg/1oralSandoz Inc1986-11-17Not applicableUs
Haloperidoltablet5 mg/1oralREMEDYREPACK INC.2010-12-21Not applicableUs
Haloperidoltablet.5 mg/1oralREMEDYREPACK INC.2014-05-13Not applicableUs
Haloperidoltablet1 mg/1oralPhysicians Total Care, Inc.1995-07-26Not applicableUs
Haloperidolsolution, concentrate2 mg/mLoralPharmaceutical Associates, Inc.2009-11-10Not applicableUs
Haloperidoltablet20 mg/1oralZydus Pharmaceuticals (USA) Inc.2008-01-03Not applicableUs
Haloperidoltablet2 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs
Haloperidoltablet20 mg/1oralAmerican Health Packaging2008-04-02Not applicableUs
Haloperidoltablet2 mg/1oralMylan Institutional Inc.2004-02-15Not applicableUs
Haloperidoltablet2 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Haloperidoltablet1 mg/1oralCardinal Health2012-09-05Not applicableUs
Haloperidoltablet5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularFresenius Kabi USA, LLC2000-10-20Not applicableUs
Haloperidoltablet1 mg/1oralClinical Solutions Wholesale1986-11-17Not applicableUs
Haloperidoltablet.5 mg/1oralSandoz Inc1986-11-17Not applicableUs
Haloperidoltablet5 mg/1oralContract Pharmacy Services Pa2010-07-28Not applicableUs
Haloperidoltablet1 mg/1oralPd Rx Pharmaceuticals, Inc.1986-06-10Not applicableUs
Haloperidolinjection5 mg/mLintramuscularCardinal Health2001-08-29Not applicableUs
Haloperidoltablet10 mg/1oralMylan Pharmaceuticals Inc.2009-07-17Not applicableUs
Haloperidoltablet10 mg/1oralMylan Institutional Inc.2009-08-03Not applicableUs
Haloperidoltablet5 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Haloperidoltablet1 mg/1oralCardinal Health1986-11-17Not applicableUs
Haloperidoltablet.5 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2011-01-13Not applicableUs
Haloperidoltablet5 mg/1oralDIRECT RX2014-01-01Not applicableUs
Haloperidoltablet10 mg/1oralSandoz Inc1988-03-11Not applicableUs
Haloperidoltablet2 mg/1oralREMEDYREPACK INC.2010-12-20Not applicableUs
Haloperidoltablet5 mg/1oralPhysicians Total Care, Inc.1996-10-24Not applicableUs
Haloperidoltablet2 mg/1oralMylan Pharmaceuticals Inc.1986-06-10Not applicableUs
Haloperidolinjection, solution5 mg/mLintramuscularCardinal Health2010-12-15Not applicableUs
Haloperidoltablet5 mg/1oralCadila Healthcare Limited2008-01-03Not applicableUs
Haloperidoltablet5 mg/1oralMc Kesson Contract Packaging2013-04-10Not applicableUs
Haloperidoltablet2 mg/1oralCardinal Health2012-09-05Not applicableUs
Haloperidoltablet10 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1988-03-11Not applicableUs
Haloperidoltablet10 mg/1oralTYA Pharmaceuticals2008-01-03Not applicableUs
Haloperidoltablet5 mg/1oralMajor Pharmaceuticals2009-02-19Not applicableUs
Haloperidoltablet1 mg/1oralDispensing Solutions, Inc.1986-11-17Not applicableUs
Haloperidoltablet5 mg/1oralMylan Institutional Inc.2004-02-15Not applicableUs
Haloperidoltablet1 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularFresenius Kabi USA, LLC2000-02-16Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularFresenius Kabi USA, LLC2000-07-12Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-06-04Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularTYA Pharmaceuticals2000-07-12Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularAmneal Agila, Llc2013-04-23Not applicableUs
Haloperidol Decanoateinjection50 mg/mLintramuscularMylan Institutional LLC2013-04-23Not applicableUs
Haloperidol Decanoateinjection100 mg/mLintramuscularTeva Parenteral Medicines, Inc.1999-07-01Not applicableUs
Haloperidol Lactateinjection, solution5 mg/mLintramuscularMylan Institutional LLC2011-05-10Not applicableUs
Haloperidol Lactateinjection, solution5 mg/mLintramuscularCardinal Health2011-05-10Not applicableUs
Haloperidol Lactateinjection5 mg/mLintramuscularGENERAL INJECTABLES AND VACCINES, INC.2015-10-13Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AloperidinJanssen-Cilag
BioperidoloFirma
BrotoponPfizer
DozicRosemont
DuraperidolNot Available
Einalon SNot Available
EukystolMerckle
HalostenShionogi Seiyaku
KeselanSumitomo
LintonTanabe Mitsubishi Pharma
Peluceslsei
SerenacePfizer
SigaperidolSiegfried
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Haloperidol decanoate
ThumbNot applicableDBSALT001195
Haloperidol lactate
ThumbNot applicableDBSALT001232
Categories
UNIIJ6292F8L3D
CAS number52-86-8
WeightAverage: 375.864
Monoisotopic: 375.140134897
Chemical FormulaC21H23ClFNO2
InChI KeyInChIKey=LNEPOXFFQSENCJ-UHFFFAOYSA-N
InChI
InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2
IUPAC Name
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
SMILES
OC1(CCN(CCCC(=O)C2=CC=C(F)C=C2)CC1)C1=CC=C(Cl)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPiperidines
Sub ClassPhenylpiperidines
Direct ParentPhenylpiperidines
Alternative Parents
Substituents
  • Phenylpiperidine
  • Phenylbutylamine
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Benzoyl
  • Aralkylamine
  • Halobenzene
  • Fluorobenzene
  • Chlorobenzene
  • Benzenoid
  • Gamma-aminoketone
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Aryl chloride
  • Tertiary alcohol
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ketone
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the management of psychotic disorders (eg. schizophrenia) and delirium, as well as to control tics and vocal utterances of Tourette's syndrome (Gilles de la Tourette's syndrome). Also used for the treatment of severe behavioural problems in children with disrubtive behaviour disorder or ADHD (attention-deficit hyperactivity disorder). Haloperidol has been used in the prevention and control of severe nausea and vomiting.
PharmacodynamicsHaloperidol is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Haloperidol principal pharmacological effects are similar to those of piperazine-derivative phenothiazines. The drug has action at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Haloperidol has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity.
Mechanism of actionThe precise mechanism whereby the therapeutic effects of haloperidol are produced is not known, but the drug appears to depress the CNS at the subcortical level of the brain, midbrain, and brain stem reticular formation. Haloperidol seems to inhibit the ascending reticular activating system of the brain stem (possibly through the caudate nucleus), thereby interrupting the impulse between the diencephalon and the cortex. The drug may antagonize the actions of glutamic acid within the extrapyramidal system, and inhibitions of catecholamine receptors may also contribute to haloperidol's mechanism of action. Haloperidol may also inhibit the reuptake of various neurotransmitters in the midbrain, and appears to have a strong central antidopaminergic and weak central anticholinergic activity. The drug produces catalepsy and inhibits spontaneous motor activity and conditioned avoidance behaviours in animals. The exact mechanism of antiemetic action of haloperidol has also not been fully determined, but the drug has been shown to directly affect the chemoreceptor trigger zone (CTZ) through the blocking of dopamine receptors in the CTZ.
Related Articles
AbsorptionOral-60%
Volume of distributionNot Available
Protein binding92%
Metabolism

Hepatic

SubstrateEnzymesProduct
Haloperidol
4-(4-chlorophenyl)-4-hydroxypiperidineDetails
Haloperidol
Reduced haloperidolDetails
Haloperidol
Haloperidol glucuronideDetails
Haloperidol
Haloperidol 1,2,3,6-tetrahydropyridineDetails
Haloperidol
fluorobenzoylpropionic acidDetails
Haloperidol
4-(4-Chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-pyridinium (HPP+)Details
Reduced haloperidol
Not Available
Haloperidol reduced pyridinium ion derivativeDetails
Haloperidol reduced pyridinium ion derivative
Haloperidol pyridinium ion derivativeDetails
Haloperidol 1,2,3,6-tetrahydropyridine
Not Available
Haloperidol pyridinium ion derivativeDetails
Route of eliminationNot Available
Half life3 weeks
ClearanceNot Available
ToxicityLD50=165 mg/kg (rats, oral)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9465
Caco-2 permeable+0.6023
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.8137
Renal organic cation transporterInhibitor0.6058
CYP450 2C9 substrateNon-substrate0.8355
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.5796
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9207
CYP450 2D6 inhibitorInhibitor0.9197
CYP450 2C19 inhibitorNon-inhibitor0.9248
CYP450 3A4 inhibitorInhibitor0.6899
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7933
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.8769
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.4367 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5
hERG inhibition (predictor II)Inhibitor0.7474
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil pharmaceutical
  • Ortho mcneil pharmaceutical inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Lederle laboratories div american cyanamid co
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Par pharmaceutical inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Roxane laboratories inc
  • Royce laboratories inc
  • Sandoz inc
  • Scs pharmaceuticals
  • Vintage pharmaceuticals llc
  • Watson laboratories inc
  • Zydus pharmaceuticals usa inc
  • Ortho mcneil janssen pharmaceutical inc
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Claris lifesciences ltd
  • Hospira inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Alpharma uspd inc
  • Morton grove pharmaceuticals inc
  • Pharmaceutical assoc inc div beach products
  • Silarx pharmaceuticals inc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
  • Ortho mcneil janssen pharmaceuticals inc
  • Abraxis pharmaceutical products
  • Akorn strides llc
  • Gland pharma ltd
  • Marsam pharmaceuticals llc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Actavis mid atlantic llc
Packagers
Dosage forms
FormRouteStrength
Liquidoral2 mg
Tabletoral.5 mg
Tabletoral1 mg
Injectionintramuscular5 mg/1
Injectionintramuscular5 mg/mL
Injection, solutionintramuscular5 mg/mL
Solutionoral2 mg/mL
Solution, concentrateoral2 mg/mL
Tabletoral.5 mg/1
Tabletoral1 mg/1
Tabletoral10 mg/1
Tabletoral2 mg/1
Tabletoral20 mg/1
Tabletoral5 mg/1
Injectionintramuscular100 mg/mL
Injectionintramuscular50 mg/mL
Liquidintramuscular5 mg
Solutionintramuscular5 mg
Liquidintramuscular100 mg
Liquidintramuscular50 mg
Tabletoral0.5 mg
Tabletoral10 mg
Tabletoral2 mg
Tabletoral20 mg
Tabletoral5 mg
Solutionoral2 mg
Solutionintramuscular100 mg
Solutionintramuscular50 mg
Prices
Unit descriptionCostUnit
Haloperidol Decanoate 100 mg/ml Solution 5ml Vial257.14USD vial
Haldol decanoate 100 ampul107.77USD ml
Haldol decanoate 50 ampul56.53USD ml
Haloperidol dec 100 mg/ml vial29.85USD ml
Haloperidol powder21.42USD g
Haloperidol dec 50 mg/ml vial17.71USD ml
Haloperidol La 100 mg/ml15.42USD ml
Haldol 5 mg/ml ampul13.4USD ml
Haloperidol La 50 mg/ml7.71USD ml
Haloperidol 5 mg/ml4.73USD ml
Haloperidol lac 5 mg/ml vial3.54USD ml
Haloperidol 20 mg tablet2.81USD tablet
Haloperidol 10 mg tablet1.46USD tablet
Haloperidol 5 mg tablet0.8USD tablet
Novo-Peridol 20 mg Tablet0.66USD tablet
Haloperidol 2 mg tablet0.49USD tablet
Haloperidol lac 2 mg/ml conc0.45USD ml
Haloperidol 1 mg tablet0.36USD tablet
Haloperidol 0.5 mg tablet0.25USD tablet
Pernox scrub cleanser0.18USD g
Apo-Haloperidol 5 mg Tablet0.16USD tablet
Novo-Peridol 5 mg Tablet0.16USD tablet
Apo-Haloperidol 10 mg Tablet0.14USD tablet
Novo-Peridol 10 mg Tablet0.14USD tablet
Apo-Haloperidol 2 mg Tablet0.11USD tablet
Novo-Peridol 2 mg Tablet0.11USD tablet
Apo-Haloperidol 1 mg Tablet0.06USD tablet
Novo-Peridol 1 mg Tablet0.06USD tablet
Apo-Haloperidol 0.5 mg Tablet0.04USD tablet
Novo-Peridol 0.5 mg Tablet0.04USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point151.5 °CPhysProp
water solubility14 mg/L (at 25 °C)MERCK INDEX (1996)
logP4.30EL TAYAR,N ET AL. (1985)
logS-4.43ADME Research, USCD
pKa8.66EL TAYAR,N ET AL. (1985)
Predicted Properties
PropertyValueSource
Water Solubility0.00446 mg/mLALOGPS
logP3.7ALOGPS
logP3.66ChemAxon
logS-4.9ALOGPS
pKa (Strongest Acidic)13.96ChemAxon
pKa (Strongest Basic)8.05ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area40.54 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity102.59 m3·mol-1ChemAxon
Polarizability39.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0079-3290000000-cc6a990404ba7b9452a8View in MoNA
1D NMR1H NMR SpectrumNot Available
1D NMR13C NMR SpectrumNot Available
References
Synthesis Reference

DrugSyn.org

US3438991
General References
  1. Niemegeers CJ, Laduron PM: Pharmacology and biochemistry of haloperidol. Proc R Soc Med. 1976;69 suppl 1:3-8. [PubMed:14331 ]
External Links
ATC CodesN05AD01
AHFS Codes
  • 28:16.08.08
PDB EntriesNot Available
FDA labelDownload (169 KB)
MSDSDownload (73.2 KB)
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetamineHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetamineHaloperidol may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Haloperidol.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with 7-Nitroindazole.
AbirateroneThe serum concentration of Haloperidol can be increased when it is combined with Abiraterone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Haloperidol.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Haloperidol.
AcepromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Aceprometazine.
AcetaminophenThe serum concentration of Haloperidol can be increased when it is combined with Acetaminophen.
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Haloperidol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Haloperidol.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Haloperidol.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Haloperidol.
adipiplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Haloperidol.
AgomelatineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Agomelatine.
AjmalineThe metabolism of Ajmaline can be decreased when combined with Haloperidol.
AlbendazoleThe serum concentration of Haloperidol can be increased when it is combined with Albendazole.
AldosteroneThe serum concentration of Haloperidol can be decreased when it is combined with Aldosterone.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Haloperidol.
AlectinibThe serum concentration of Haloperidol can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfaxalone.
AlfentanilThe serum concentration of Haloperidol can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alfentanil.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Haloperidol.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Haloperidol.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Haloperidol.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Haloperidol.
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Haloperidol.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Haloperidol.
AlprenololThe metabolism of Alprenolol can be decreased when combined with Haloperidol.
AmantadineAmantadine may increase the QTc-prolonging activities of Haloperidol.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Haloperidol.
Aminohippuric acidThe serum concentration of Haloperidol can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Haloperidol.
AmiodaroneHaloperidol may increase the QTc-prolonging activities of Amiodarone.
AmiodaroneThe serum concentration of Haloperidol can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amisulpride.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Haloperidol.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Haloperidol.
AmlodipineThe serum concentration of Haloperidol can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amobarbital.
AmoxapineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Amperozide.
AmphetamineHaloperidol may decrease the stimulatory activities of Amphetamine.
AmprenavirThe serum concentration of Haloperidol can be decreased when it is combined with Amprenavir.
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Haloperidol.
AmsacrineThe serum concentration of Haloperidol can be increased when it is combined with Amsacrine.
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Haloperidol.
AnagrelideHaloperidol may increase the QTc-prolonging activities of Anagrelide.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Haloperidol.
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Haloperidol.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Haloperidol.
ApomorphineApomorphine may increase the QTc-prolonging activities of Haloperidol.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Haloperidol.
AprepitantThe serum concentration of Haloperidol can be increased when it is combined with Aprepitant.
AprindineThe metabolism of Aprindine can be decreased when combined with Haloperidol.
ArformoterolArformoterol may increase the QTc-prolonging activities of Haloperidol.
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Haloperidol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Haloperidol.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Haloperidol.
ArmodafinilThe metabolism of Haloperidol can be decreased when combined with Armodafinil.
Arsenic trioxideHaloperidol may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherHaloperidol may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Haloperidol can be decreased when combined with Artemether.
ArticaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Articaine.
AsenapineHaloperidol may increase the QTc-prolonging activities of Asenapine.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Haloperidol.
AstemizoleThe serum concentration of Haloperidol can be increased when it is combined with Astemizole.
AstemizoleThe metabolism of Astemizole can be decreased when combined with Haloperidol.
AtazanavirAtazanavir may increase the QTc-prolonging activities of Haloperidol.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Haloperidol.
AtenololThe serum concentration of Haloperidol can be increased when it is combined with Atenolol.
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Haloperidol.
AtomoxetineThe metabolism of Atomoxetine can be decreased when combined with Haloperidol.
AtorvastatinThe serum concentration of Haloperidol can be increased when it is combined with Atorvastatin.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Haloperidol.
AzaperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Azaperone.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Haloperidol.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Haloperidol.
AzelastineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzithromycinHaloperidol may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe serum concentration of Haloperidol can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Baclofen.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Haloperidol.
BarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Barbital.
BedaquilineHaloperidol may increase the QTc-prolonging activities of Bedaquiline.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Haloperidol.
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Haloperidol.
BenzocaineThe serum concentration of Haloperidol can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Haloperidol.
BenzphetamineHaloperidol may decrease the stimulatory activities of Benzphetamine.
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Haloperidol.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Haloperidol.
BepridilThe serum concentration of Haloperidol can be increased when it is combined with Bepridil.
BepridilThe metabolism of Bepridil can be decreased when combined with Haloperidol.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Haloperidol.
BetaxololThe metabolism of Haloperidol can be decreased when combined with Betaxolol.
BexaroteneThe serum concentration of Haloperidol can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Haloperidol can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Haloperidol.
BoceprevirThe metabolism of Haloperidol can be decreased when combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Haloperidol.
BortezomibBortezomib may increase the QTc-prolonging activities of Haloperidol.
BortezomibThe metabolism of Bortezomib can be decreased when combined with Haloperidol.
BosentanThe serum concentration of Haloperidol can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Haloperidol.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Haloperidol.
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Haloperidol.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Haloperidol.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
BrimonidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Bromazepam.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Haloperidol.
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Haloperidol.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Haloperidol.
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Haloperidol.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Haloperidol.
BrotizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Brotizolam.
BufuralolThe metabolism of Bufuralol can be decreased when combined with Haloperidol.
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Haloperidol.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Haloperidol.
BuprenorphineThe serum concentration of Haloperidol can be increased when it is combined with Buprenorphine.
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Haloperidol.
BupropionThe metabolism of Bupropion can be decreased when combined with Haloperidol.
BuserelinBuserelin may increase the QTc-prolonging activities of Haloperidol.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Haloperidol.
BuspironeThe metabolism of Buspirone can be decreased when combined with Haloperidol.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Haloperidol.
ButacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Haloperidol.
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Haloperidol.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Haloperidol.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Haloperidol.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Haloperidol.
CandesartanThe serum concentration of Haloperidol can be increased when it is combined with Candesartan.
CapecitabineThe metabolism of Haloperidol can be decreased when combined with Capecitabine.
CaptoprilThe serum concentration of Haloperidol can be increased when it is combined with Captopril.
CaptoprilThe metabolism of Captopril can be decreased when combined with Haloperidol.
CarbamazepineThe serum concentration of Haloperidol can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Haloperidol.
CarbinoxamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Haloperidol.
CariprazineThe metabolism of Cariprazine can be decreased when combined with Haloperidol.
CarisoprodolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Carisoprodol.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Haloperidol.
CarteololThe metabolism of Carteolol can be decreased when combined with Haloperidol.
CarvedilolThe serum concentration of Haloperidol can be increased when it is combined with Carvedilol.
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Haloperidol.
CaspofunginThe serum concentration of Haloperidol can be increased when it is combined with Caspofungin.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Haloperidol.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Haloperidol.
CephalexinThe metabolism of Cephalexin can be decreased when combined with Haloperidol.
CeritinibThe serum concentration of Haloperidol can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Haloperidol.
CetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be decreased when combined with Haloperidol.
Chloral hydrateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Haloperidol can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Haloperidol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Haloperidol.
ChlormezanoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Haloperidol.
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Haloperidol.
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Haloperidol.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Haloperidol.
ChlorphentermineHaloperidol may decrease the stimulatory activities of Chlorphentermine.
ChlorpromazineThe serum concentration of Haloperidol can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Haloperidol can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Haloperidol can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chlorprothixene.
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Haloperidol.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Haloperidol.
CholecalciferolThe metabolism of Haloperidol can be decreased when combined with Cholecalciferol.
CholesterolThe serum concentration of Haloperidol can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Haloperidol can be decreased when it is combined with Cholic Acid.
CilazaprilThe serum concentration of Haloperidol can be increased when it is combined with Cilazapril.
CilostazolThe metabolism of Cilostazol can be decreased when combined with Haloperidol.
CimetidineThe serum concentration of Haloperidol can be decreased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Haloperidol.
CinacalcetThe metabolism of Haloperidol can be decreased when combined with Cinacalcet.
CinchocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cinchocaine.
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Haloperidol.
CiprofloxacinThe serum concentration of Haloperidol can be increased when it is combined with Ciprofloxacin.
CisaprideHaloperidol may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Haloperidol.
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Haloperidol.
CitalopramHaloperidol may increase the QTc-prolonging activities of Citalopram.
ClarithromycinThe serum concentration of Haloperidol can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Haloperidol can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clemastine.
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Haloperidol.
ClidiniumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clidinium.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Haloperidol.
ClobazamThe metabolism of Haloperidol can be decreased when combined with Clobazam.
ClofazimineThe serum concentration of Haloperidol can be increased when it is combined with Clofazimine.
clomethiazoleThe risk or severity of adverse effects can be increased when Haloperidol is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Haloperidol.
ClomipramineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Haloperidol.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Haloperidol.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Haloperidol.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Haloperidol.
ClorazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Clorazepate.
ClotrimazoleThe metabolism of Haloperidol can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Haloperidol.
ClozapineThe metabolism of Haloperidol can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Haloperidol can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Haloperidol.
CocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cocaine.
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Haloperidol.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Haloperidol.
ColchicineThe serum concentration of Haloperidol can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Haloperidol can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Haloperidol can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Haloperidol.
CrizotinibThe metabolism of Haloperidol can be decreased when combined with Crizotinib.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Haloperidol.
CyclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyclizine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Haloperidol.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.
CyclophosphamideThe serum concentration of Haloperidol can be increased when it is combined with Cyclophosphamide.
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Haloperidol.
CyclosporineThe metabolism of Haloperidol can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Haloperidol.
CyproheptadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Haloperidol can be decreased when it is combined with Cyproterone acetate.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Haloperidol.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Haloperidol.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Haloperidol.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Haloperidol.
DaclatasvirThe serum concentration of Haloperidol can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Haloperidol can be increased when it is combined with Dactinomycin.
DantroleneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Haloperidol.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Haloperidol.
DapoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dapoxetine.
DarifenacinThe metabolism of Haloperidol can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Haloperidol can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Haloperidol.
DasatinibThe serum concentration of Haloperidol can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Haloperidol can be decreased when it is combined with Daunorubicin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Haloperidol.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Haloperidol.
DeferasiroxThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Haloperidol.
DelavirdineThe metabolism of Haloperidol can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when Haloperidol is combined with deramciclane.
DesfluraneDesflurane may increase the QTc-prolonging activities of Haloperidol.
DesfluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desflurane.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Haloperidol.
DesipramineThe metabolism of Desipramine can be decreased when combined with Haloperidol.
DesloratadineThe serum concentration of Haloperidol can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Desloratadine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Haloperidol.
DetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Detomidine.
DexamethasoneThe serum concentration of Haloperidol can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Haloperidol.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Haloperidol.
DexmedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dexmedetomidine.
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Haloperidol.
DextroamphetamineHaloperidol may decrease the stimulatory activities of Dextroamphetamine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Haloperidol.
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Haloperidol.
DextromoramideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Haloperidol.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Haloperidol.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Haloperidol.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Haloperidol.
DifenoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Difenoxin.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Haloperidol.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Haloperidol.
DigoxinThe serum concentration of Haloperidol can be decreased when it is combined with Digoxin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Haloperidol.
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Haloperidol.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Haloperidol.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Haloperidol.
DihydroetorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Haloperidol.
DiltiazemThe metabolism of Haloperidol can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be increased when it is combined with Haloperidol.
DimenhydrinateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dimenhydrinate.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Haloperidol.
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Haloperidol.
DiphenoxylateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Haloperidol can be increased when it is combined with Dipyridamole.
DisopyramideHaloperidol may increase the QTc-prolonging activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Haloperidol.
DofetilideHaloperidol may increase the QTc-prolonging activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Haloperidol.
DolasetronThe metabolism of Dolasetron can be decreased when combined with Haloperidol.
DomperidoneHaloperidol may increase the QTc-prolonging activities of Domperidone.
DonepezilThe metabolism of Donepezil can be decreased when combined with Haloperidol.
DopamineThe metabolism of Dopamine can be decreased when combined with Haloperidol.
DoramectinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Doramectin.
DoxazosinThe serum concentration of Haloperidol can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Haloperidol.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Haloperidol.
DoxepinThe metabolism of Doxepin can be decreased when combined with Haloperidol.
DoxorubicinThe serum concentration of Haloperidol can be decreased when it is combined with Doxorubicin.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Haloperidol.
DoxycyclineThe metabolism of Haloperidol can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DoxylamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Haloperidol is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
DronedaroneHaloperidol may increase the QTc-prolonging activities of Dronedarone.
DronedaroneThe metabolism of Haloperidol can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Haloperidol.
DrotebanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Drotebanol.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Haloperidol.
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Haloperidol.
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Haloperidol.
DyclonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Dyclonine.
EcgonineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Haloperidol is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Haloperidol.
EfavirenzThe serum concentration of Haloperidol can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Haloperidol is combined with Efavirenz.
ElbasvirThe serum concentration of Haloperidol can be increased when it is combined with Elbasvir.
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Haloperidol.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Haloperidol.
EliglustatHaloperidol may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Haloperidol can be decreased when combined with Eliglustat.
EnalaprilThe serum concentration of Haloperidol can be increased when it is combined with Enalapril.
EncainideThe metabolism of Encainide can be decreased when combined with Haloperidol.
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Haloperidol.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Haloperidol.
EntacaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Entacapone.
EnzalutamideThe serum concentration of Haloperidol can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Haloperidol.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Haloperidol.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Haloperidol.
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Haloperidol.
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Haloperidol.
EribulinEribulin may increase the QTc-prolonging activities of Haloperidol.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Haloperidol.
ErythromycinThe metabolism of Haloperidol can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Haloperidol.
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Haloperidol.
EscitalopramHaloperidol may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Haloperidol can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Haloperidol.
EsomeprazoleThe metabolism of Haloperidol can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Haloperidol.
EstramustineThe serum concentration of Haloperidol can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Haloperidol can be decreased when it is combined with Estriol.
EstriolThe serum concentration of Estriol can be increased when it is combined with Haloperidol.
EstroneThe serum concentration of Haloperidol can be decreased when it is combined with Estrone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Haloperidol.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Haloperidol.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Haloperidol.
EthanolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Haloperidol.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Haloperidol.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Haloperidol.
EthosuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethotoin.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl loflazepate.
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Haloperidol.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Haloperidol.
EtidocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etizolam.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Haloperidol.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Haloperidol.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Haloperidol.
EtoperidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etoperidone.
EtoposideThe serum concentration of Haloperidol can be increased when it is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Haloperidol.
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Haloperidol.
EtorphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Etorphine.
EtravirineThe serum concentration of Haloperidol can be decreased when it is combined with Etravirine.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Haloperidol.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Haloperidol.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Haloperidol.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Haloperidol.
EzogabineEzogabine may increase the QTc-prolonging activities of Haloperidol.
EzogabineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ezogabine.
FamotidineFamotidine may increase the QTc-prolonging activities of Haloperidol.
FelbamateFelbamate may increase the QTc-prolonging activities of Haloperidol.
FelbamateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Felbamate.
FelodipineThe serum concentration of Haloperidol can be increased when it is combined with Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Haloperidol.
FencamfamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fencamfamine.
FenfluramineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fenfluramine.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Haloperidol.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Haloperidol.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Haloperidol.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Haloperidol.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Haloperidol.
FingolimodFingolimod may increase the QTc-prolonging activities of Haloperidol.
FingolimodThe metabolism of Fingolimod can be decreased when combined with Haloperidol.
FlecainideFlecainide may increase the QTc-prolonging activities of Haloperidol.
FlecainideThe metabolism of Flecainide can be decreased when combined with Haloperidol.
FlibanserinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flibanserin.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Haloperidol.
FloxuridineThe metabolism of Haloperidol can be decreased when combined with Floxuridine.
FluconazoleFluconazole may increase the QTc-prolonging activities of Haloperidol.
FludiazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fludiazepam.
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Haloperidol.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Haloperidol.
FlunitrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flunitrazepam.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Haloperidol.
FluorouracilThe metabolism of Haloperidol can be decreased when combined with Fluorouracil.
FluoxetineFluoxetine may increase the QTc-prolonging activities of Haloperidol.
FlupentixolHaloperidol may increase the QTc-prolonging activities of Flupentixol.
FlupentixolThe serum concentration of Haloperidol can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Haloperidol can be increased when it is combined with Fluphenazine.
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Haloperidol.
FlurazepamThe serum concentration of Haloperidol can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Flurazepam.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Haloperidol.
FluspirileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluspirilene.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Haloperidol.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Haloperidol.
FluvoxamineThe serum concentration of Haloperidol can be increased when it is combined with Fluvoxamine.
FluvoxamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Haloperidol.
FormoterolThe metabolism of Formoterol can be decreased when combined with Haloperidol.
FosamprenavirThe metabolism of Haloperidol can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Haloperidol can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Haloperidol.
FosphenytoinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Fospropofol.
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Haloperidol.
Fusidic AcidThe serum concentration of Haloperidol can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Haloperidol is combined with gabapentin enacarbil.
Gadobenic acidHaloperidol may increase the QTc-prolonging activities of Gadobenic acid.
GalantamineGalantamine may increase the QTc-prolonging activities of Haloperidol.
GalantamineThe metabolism of Galantamine can be decreased when combined with Haloperidol.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Haloperidol is combined with Gamma Hydroxybutyric Acid.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Haloperidol.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Haloperidol.
GemfibrozilThe metabolism of Haloperidol can be decreased when combined with Gemfibrozil.
GemifloxacinHaloperidol may increase the QTc-prolonging activities of Gemifloxacin.
GenisteinThe serum concentration of Haloperidol can be increased when it is combined with Genistein.
GlutethimideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Glutethimide.
GlyburideThe serum concentration of Haloperidol can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Haloperidol can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Haloperidol.
GlycopyrroniumThe serum concentration of Haloperidol can be decreased when it is combined with Glycopyrronium.
GoserelinGoserelin may increase the QTc-prolonging activities of Haloperidol.
Gramicidin DThe serum concentration of Haloperidol can be increased when it is combined with Gramicidin D.
GranisetronGranisetron may increase the QTc-prolonging activities of Haloperidol.
GranisetronThe metabolism of Granisetron can be decreased when combined with Haloperidol.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Haloperidol.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Haloperidol.
GuanfacineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Haloperidol.
HalothaneThe metabolism of Halothane can be decreased when combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Haloperidol.
HeroinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Heroin.
HexobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hexobarbital.
HistrelinHistrelin may increase the QTc-prolonging activities of Haloperidol.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Haloperidol.
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Haloperidol.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Haloperidol.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Haloperidol.
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Haloperidol.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Haloperidol.
Hydroxyamphetamine hydrobromideHaloperidol may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
HydroxyzineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Hydroxyzine.
IbandronateIbandronate may increase the QTc-prolonging activities of Haloperidol.
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Haloperidol.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Haloperidol.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Haloperidol.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Haloperidol.
IbutilideHaloperidol may increase the QTc-prolonging activities of Ibutilide.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Haloperidol.
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Haloperidol.
IdelalisibThe serum concentration of Haloperidol can be increased when it is combined with Idelalisib.
IloperidoneHaloperidol may increase the QTc-prolonging activities of Iloperidone.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Haloperidol.
ImatinibThe metabolism of Haloperidol can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Haloperidol.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Haloperidol.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Haloperidol.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Haloperidol.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Haloperidol.
IndalpineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Indalpine.
IndapamideIndapamide may increase the QTc-prolonging activities of Haloperidol.
IndinavirThe serum concentration of Haloperidol can be decreased when it is combined with Indinavir.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Haloperidol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Haloperidol.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Haloperidol.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Haloperidol.
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.
IrbesartanThe metabolism of Haloperidol can be decreased when combined with Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Haloperidol.
IsavuconazoniumThe metabolism of Haloperidol can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Haloperidol.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Haloperidol.
IsofluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Isoflurane.
IsoniazidThe metabolism of Haloperidol can be decreased when combined with Isoniazid.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Haloperidol.
IsradipineIsradipine may increase the QTc-prolonging activities of Haloperidol.
ItraconazoleItraconazole may increase the QTc-prolonging activities of Haloperidol.
IvabradineIvabradine may increase the QTc-prolonging activities of Haloperidol.
IvacaftorThe serum concentration of Haloperidol can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Haloperidol.
IxazomibThe metabolism of Ixazomib can be decreased when combined with Haloperidol.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Haloperidol.
KetamineThe serum concentration of Haloperidol can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Haloperidol.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Haloperidol.
KetobemidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ketobemidone.
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Haloperidol.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Haloperidol.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Haloperidol.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Haloperidol.
LabetalolThe metabolism of Labetalol can be decreased when combined with Haloperidol.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Haloperidol.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Haloperidol.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Haloperidol.
LansoprazoleThe serum concentration of Haloperidol can be increased when it is combined with Lansoprazole.
LapatinibLapatinib may increase the QTc-prolonging activities of Haloperidol.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Haloperidol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Haloperidol.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Haloperidol.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Haloperidol.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Haloperidol.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Haloperidol.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Haloperidol.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Haloperidol.
LevobupivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levocetirizine.
LevodopaThe metabolism of Levodopa can be decreased when combined with Haloperidol.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Haloperidol.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Haloperidol.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomethadyl Acetate.
LevomilnacipranThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Levorphanol.
LevothyroxineThe serum concentration of Haloperidol can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Haloperidol can be increased when it is combined with Lidocaine.
LidocaineThe metabolism of Lidocaine can be decreased when combined with Haloperidol.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Haloperidol.
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Haloperidol.
LiothyronineThe serum concentration of Haloperidol can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Haloperidol can be decreased when it is combined with Liotrix.
LisdexamfetamineHaloperidol may decrease the stimulatory activities of Lisdexamfetamine.
LisinoprilThe serum concentration of Haloperidol can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be decreased when combined with Haloperidol.
LithiumLithium may increase the neurotoxic activities of Haloperidol.
LithiumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lofentanil.
LomitapideThe serum concentration of Haloperidol can be increased when it is combined with Lomitapide.
LomustineThe metabolism of Lomustine can be decreased when combined with Haloperidol.
LoperamideThe serum concentration of Haloperidol can be increased when it is combined with Loperamide.
LopinavirHaloperidol may increase the QTc-prolonging activities of Lopinavir.
LopinavirThe serum concentration of Haloperidol can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Haloperidol can be increased when it is combined with Loratadine.
LoratadineThe metabolism of Loratadine can be decreased when combined with Haloperidol.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Haloperidol.
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Haloperidol.
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Haloperidol.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Haloperidol.
LosartanThe serum concentration of Haloperidol can be increased when it is combined with Losartan.
LovastatinThe metabolism of Haloperidol can be decreased when combined with Lovastatin.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Haloperidol.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Haloperidol.
Lu AA21004The risk or severity of adverse effects can be increased when Haloperidol is combined with Lu AA21004.
LuliconazoleThe serum concentration of Haloperidol can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Haloperidol can be decreased when it is combined with Lumacaftor.
LumefantrineHaloperidol may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Haloperidol can be decreased when combined with Lumefantrine.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Haloperidol.
LurasidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Lurasidone.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Haloperidol.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Magnesium Sulfate.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Haloperidol.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Haloperidol.
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Haloperidol.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Haloperidol.
MebendazoleThe serum concentration of Haloperidol can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meclizine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Haloperidol.
MedetomidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Medetomidine.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Haloperidol.
MefloquineMefloquine may increase the QTc-prolonging activities of Haloperidol.
Megestrol acetateThe serum concentration of Haloperidol can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melatonin.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Haloperidol.
MelperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Melperone.
MephentermineHaloperidol may decrease the stimulatory activities of Mephentermine.
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Haloperidol.
MepivacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Mepivacaine.
MeprobamateThe serum concentration of Haloperidol can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Meprobamate.
MequitazineThe metabolism of Mequitazine can be decreased when combined with Haloperidol.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Haloperidol.
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Haloperidol.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Haloperidol.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.
MetaxaloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Metaxalone.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Haloperidol.
MethadoneThe metabolism of Methadone can be decreased when combined with Haloperidol.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methadyl Acetate.
MethamphetamineHaloperidol may decrease the stimulatory activities of Methamphetamine.
MethapyrileneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methaqualone.
MethocarbamolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Haloperidol.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Haloperidol.
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Haloperidol.
MethotrimeprazineThe metabolism of Methotrimeprazine can be decreased when combined with Haloperidol.
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Haloperidol.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Haloperidol.
MethsuximideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.
MethylphenidateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenidate.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Haloperidol.
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Haloperidol.
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Haloperidol.
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Haloperidol.
MetoprololThe serum concentration of Haloperidol can be increased when it is combined with Metoprolol.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Haloperidol.
MetyrosineHaloperidol may increase the sedative activities of Metyrosine.
MetyrosineThe risk or severity of adverse effects can be increased when Metyrosine is combined with Haloperidol.
MexiletineThe metabolism of Haloperidol can be decreased when combined with Mexiletine.
MianserinThe metabolism of Mianserin can be decreased when combined with Haloperidol.
MibefradilThe serum concentration of Haloperidol can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Haloperidol can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Haloperidol can be decreased when it is combined with Midazolam.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Haloperidol.
MifepristoneMifepristone may increase the QTc-prolonging activities of Haloperidol.
MilnacipranThe risk or severity of adverse effects can be increased when Haloperidol is combined with Milnacipran.
MinaprineThe metabolism of Minaprine can be decreased when combined with Haloperidol.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
MirabegronMirabegron may increase the QTc-prolonging activities of Haloperidol.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Haloperidol.
MirtazapineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Haloperidol.
MitomycinThe serum concentration of Haloperidol can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Haloperidol can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Haloperidol can be decreased when it is combined with Mitoxantrone.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Haloperidol.
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Haloperidol.
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Haloperidol.
ModafinilThe serum concentration of Haloperidol can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Haloperidol.
MolindoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Molindone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Haloperidol.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Haloperidol.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Haloperidol.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Haloperidol.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.
NabiloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nabilone.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Haloperidol.
NadololThe serum concentration of Nadolol can be increased when it is combined with Haloperidol.
NafcillinThe serum concentration of Haloperidol can be decreased when it is combined with Nafcillin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Haloperidol.
NalbuphineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Haloperidol.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Haloperidol.
NaltrexoneThe serum concentration of Haloperidol can be increased when it is combined with Naltrexone.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Haloperidol.
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Haloperidol.
NaringeninThe serum concentration of Haloperidol can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be decreased when combined with Haloperidol.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Haloperidol.
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Haloperidol.
NefazodoneThe risk or severity of adverse effects can be increased when Nefazodone is combined with Haloperidol.
NefazodoneThe metabolism of Nefazodone can be decreased when combined with Haloperidol.
NelfinavirNelfinavir may increase the QTc-prolonging activities of Haloperidol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Haloperidol.
NeostigmineThe serum concentration of Haloperidol can be increased when it is combined with Neostigmine.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Haloperidol.
NetupitantThe serum concentration of Haloperidol can be increased when it is combined with Netupitant.
NetupitantThe metabolism of Netupitant can be decreased when combined with Haloperidol.
NevirapineThe metabolism of Haloperidol can be decreased when combined with Nevirapine.
NicardipineNicardipine may increase the QTc-prolonging activities of Haloperidol.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Haloperidol.
NicergolineThe metabolism of Nicergoline can be decreased when combined with Haloperidol.
NicotineThe metabolism of Nicotine can be decreased when combined with Haloperidol.
NifedipineThe serum concentration of Haloperidol can be decreased when it is combined with Nifedipine.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Haloperidol.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Haloperidol.
NilotinibHaloperidol may increase the QTc-prolonging activities of Nilotinib.
NilotinibThe metabolism of Haloperidol can be decreased when combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Haloperidol.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Haloperidol.
NisoldipineThe serum concentration of Haloperidol can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Haloperidol can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrazepam.
NitrendipineThe serum concentration of Haloperidol can be increased when it is combined with Nitrendipine.
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Haloperidol.
Nitrous oxideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Haloperidol.
NorethisteroneThe serum concentration of Haloperidol can be decreased when it is combined with Norethisterone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Haloperidol.
NormethadoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Normethadone.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Haloperidol.
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Haloperidol.
OctreotideOctreotide may increase the QTc-prolonging activities of Haloperidol.
OfloxacinHaloperidol may increase the QTc-prolonging activities of Ofloxacin.
OlanzapineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Olanzapine.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Haloperidol.
OlaparibThe metabolism of Haloperidol can be decreased when combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Haloperidol.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Haloperidol.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Haloperidol.
OmeprazoleThe serum concentration of Haloperidol can be increased when it is combined with Omeprazole.
OndansetronThe metabolism of Ondansetron can be decreased when combined with Haloperidol.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Haloperidol.
OpiumThe risk or severity of adverse effects can be increased when Haloperidol is combined with Opium.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Haloperidol.
OrphenadrineHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Haloperidol.
OsanetantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Osanetant.
OsimertinibThe serum concentration of Haloperidol can be increased when it is combined with Osimertinib.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Haloperidol.
OxazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxazepam.
OxprenololThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxprenolol.
OxybuprocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Oxybuprocaine.
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Haloperidol.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Haloperidol.
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Haloperidol.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Haloperidol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Haloperidol.
OxytocinOxytocin may increase the QTc-prolonging activities of Haloperidol.
P-NitrophenolThe serum concentration of Haloperidol can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Haloperidol can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Haloperidol can be increased when it is combined with Palbociclib.
PaliperidoneHaloperidol may increase the QTc-prolonging activities of Paliperidone.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Haloperidol.
Palmitic AcidThe serum concentration of Haloperidol can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Haloperidol.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Haloperidol.
PanobinostatThe metabolism of Haloperidol can be decreased when combined with Panobinostat.
PantoprazoleThe serum concentration of Haloperidol can be increased when it is combined with Pantoprazole.
ParaldehydeHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Haloperidol.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Haloperidol.
ParoxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Haloperidol.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Haloperidol.
PazopanibPazopanib may increase the QTc-prolonging activities of Haloperidol.
Peginterferon alfa-2bThe serum concentration of Haloperidol can be decreased when it is combined with Peginterferon alfa-2b.
PentamidinePentamidine may increase the QTc-prolonging activities of Haloperidol.
PentamidineThe metabolism of Pentamidine can be decreased when combined with Haloperidol.
PentazocineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Haloperidol.
PerampanelThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perampanel.
PerflutrenHaloperidol may increase the QTc-prolonging activities of Perflutren.
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Haloperidol.
PerindoprilThe serum concentration of Haloperidol can be increased when it is combined with Perindopril.
PerospironeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Perospirone.
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Haloperidol.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Haloperidol.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Haloperidol.
PethidineThe metabolism of Pethidine can be decreased when combined with Haloperidol.
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Haloperidol.
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Haloperidol.
PhenforminThe metabolism of Phenformin can be decreased when combined with Haloperidol.
PhenobarbitalThe serum concentration of Haloperidol can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Haloperidol.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Phenoxyethanol.
PhentermineHaloperidol may decrease the stimulatory activities of Phentermine.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Haloperidol.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Haloperidol.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Haloperidol.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Haloperidol.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Haloperidol.
PimozideHaloperidol may increase the QTc-prolonging activities of Pimozide.
PimozideThe serum concentration of Haloperidol can be increased when it is combined with Pimozide.
PindololThe metabolism of Pindolol can be decreased when combined with Haloperidol.
PipamperoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pipamperone.
PiperazineThe metabolism of Piperazine can be decreased when combined with Haloperidol.
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Haloperidol.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Haloperidol.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Haloperidol.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Haloperidol.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Haloperidol.
PizotifenThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Haloperidol can be decreased when it is combined with Platelet Activating Factor.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Haloperidol.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Haloperidol.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Haloperidol.
PosaconazolePosaconazole may increase the QTc-prolonging activities of Haloperidol.
PramipexoleHaloperidol may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Pramocaine.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Haloperidol.
PrazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam.
PrazosinThe serum concentration of Haloperidol can be increased when it is combined with Prazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Haloperidol.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Haloperidol.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Haloperidol.
PrilocaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Prilocaine.
PrimaquineHaloperidol may increase the QTc-prolonging activities of Primaquine.
PrimidoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Primidone.
ProbenecidThe serum concentration of Haloperidol can be increased when it is combined with Probenecid.
ProcainamideHaloperidol may increase the QTc-prolonging activities of Procainamide.
ProcaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Procaine.
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Haloperidol.
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Haloperidol.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Haloperidol.
ProgesteroneThe serum concentration of Haloperidol can be decreased when it is combined with Progesterone.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Haloperidol.
PromazineThe metabolism of Haloperidol can be decreased when combined with Promazine.
PromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Promazine.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Haloperidol.
PromethazineThe metabolism of Promethazine can be decreased when combined with Haloperidol.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Haloperidol.
PropafenoneThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.
PropafenoneThe metabolism of Propafenone can be decreased when combined with Haloperidol.
ProparacaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Proparacaine.
PropofolPropofol may increase the QTc-prolonging activities of Haloperidol.
PropofolThe metabolism of Propofol can be decreased when combined with Haloperidol.
PropoxycaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Haloperidol.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Haloperidol.
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Haloperidol.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Haloperidol.
PSD502The risk or severity of adverse effects can be increased when Haloperidol is combined with PSD502.
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Haloperidol.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Haloperidol.
PyrimethamineThe metabolism of Haloperidol can be decreased when combined with Pyrimethamine.
QuazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Quazepam.
QuercetinThe serum concentration of Haloperidol can be increased when it is combined with Quercetin.
QuetiapineHaloperidol may increase the QTc-prolonging activities of Quetiapine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Haloperidol.
QuinacrineThe serum concentration of Haloperidol can be increased when it is combined with Quinacrine.
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Haloperidol.
QuinidineHaloperidol may increase the QTc-prolonging activities of Quinidine.
QuinidineThe serum concentration of Haloperidol can be increased when it is combined with Quinidine.
QuinineHaloperidol may increase the QTc-prolonging activities of Quinine.
QuinineThe serum concentration of Haloperidol can be increased when it is combined with Quinine.
RamelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ramelteon.
RanitidineThe serum concentration of Haloperidol can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Haloperidol.
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Haloperidol.
ReboxetineThe serum concentration of Haloperidol can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Haloperidol can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Remifentanil.
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Haloperidol.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Haloperidol.
repinotanThe metabolism of repinotan can be decreased when combined with Haloperidol.
ReserpineThe serum concentration of Haloperidol can be decreased when it is combined with Reserpine.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Haloperidol.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Haloperidol.
RifabutinThe metabolism of Haloperidol can be increased when combined with Rifabutin.
RifampicinThe serum concentration of Haloperidol can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Haloperidol.
RifapentineThe metabolism of Haloperidol can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Haloperidol.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Haloperidol.
RisperidoneRisperidone may increase the QTc-prolonging activities of Haloperidol.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Haloperidol.
RitonavirRitonavir may increase the QTc-prolonging activities of Haloperidol.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Haloperidol.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Haloperidol.
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Haloperidol.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Haloperidol.
RolapitantThe serum concentration of Haloperidol can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Haloperidol.
RomifidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Romifidine.
RopiniroleHaloperidol may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Haloperidol can be decreased when combined with Ropinirole.
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Haloperidol.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Haloperidol.
RotigotineHaloperidol may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Haloperidol.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Haloperidol is combined with S-Ethylisothiourea.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Haloperidol.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Haloperidol.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Haloperidol.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Haloperidol.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Haloperidol.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Haloperidol.
SaquinavirThe serum concentration of Haloperidol can be decreased when it is combined with Saquinavir.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Haloperidol.
ScopolamineThe serum concentration of Haloperidol can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Haloperidol.
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Haloperidol.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Haloperidol.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Haloperidol.
SertindoleThe metabolism of Sertindole can be decreased when combined with Haloperidol.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Haloperidol.
SertralineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sertraline.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Haloperidol.
SevofluraneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sevoflurane.
SildenafilThe metabolism of Haloperidol can be decreased when combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Haloperidol.
SiltuximabThe serum concentration of Haloperidol can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Haloperidol can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Haloperidol can be increased when it is combined with Simvastatin.
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Haloperidol.
SirolimusThe serum concentration of Haloperidol can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Haloperidol.
Sodium oxybateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sodium oxybate.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Haloperidol.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Haloperidol.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Haloperidol.
SorafenibSorafenib may increase the QTc-prolonging activities of Haloperidol.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Haloperidol.
SotalolHaloperidol may increase the QTc-prolonging activities of Sotalol.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Haloperidol.
SparteineThe metabolism of Sparteine can be decreased when combined with Haloperidol.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Haloperidol.
SpironolactoneThe serum concentration of Haloperidol can be increased when it is combined with Spironolactone.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Haloperidol.
St. John's WortThe serum concentration of Haloperidol can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Haloperidol can be increased when it is combined with Staurosporine.
StiripentolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Stiripentol.
StreptozocinThe serum concentration of Haloperidol can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.
SulfadiazineThe metabolism of Haloperidol can be decreased when combined with Sulfadiazine.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Haloperidol.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Haloperidol.
SulfinpyrazoneThe serum concentration of Haloperidol can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleHaloperidol may increase the QTc-prolonging activities of Sulfisoxazole.
SulfisoxazoleThe metabolism of Haloperidol can be decreased when combined with Sulfisoxazole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Haloperidol.
SulpirideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sulpiride.
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Haloperidol.
SunitinibSunitinib may increase the QTc-prolonging activities of Haloperidol.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Haloperidol.
SuvorexantThe risk or severity of adverse effects can be increased when Haloperidol is combined with Suvorexant.
TacrineThe serum concentration of Haloperidol can be increased when it is combined with Tacrine.
TacrolimusThe serum concentration of Haloperidol can be decreased when it is combined with Tacrolimus.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Haloperidol.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Haloperidol.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Haloperidol.
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Haloperidol.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Haloperidol.
TapentadolThe metabolism of Tapentadol can be decreased when combined with Haloperidol.
TasimelteonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tasimelteon.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Haloperidol.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Haloperidol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Haloperidol.
TegaserodThe metabolism of Tegaserod can be decreased when combined with Haloperidol.
TelaprevirThe metabolism of Haloperidol can be decreased when combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Haloperidol.
TelavancinHaloperidol may increase the QTc-prolonging activities of Telavancin.
TelithromycinHaloperidol may increase the QTc-prolonging activities of Telithromycin.
TelmisartanThe serum concentration of Haloperidol can be increased when it is combined with Telmisartan.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Haloperidol.
TenofovirThe metabolism of Haloperidol can be decreased when combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Haloperidol.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Haloperidol.
TerazosinThe serum concentration of Haloperidol can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Haloperidol can be decreased when combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Haloperidol.
TerfenadineThe serum concentration of Haloperidol can be increased when it is combined with Terfenadine.
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Haloperidol.
TeriflunomideThe serum concentration of Haloperidol can be decreased when it is combined with Teriflunomide.
TesmilifeneThe serum concentration of Haloperidol can be decreased when it is combined with Tesmilifene.
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Haloperidol.
TestosteroneThe serum concentration of Haloperidol can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Haloperidol.
TetrabenazineHaloperidol may increase the QTc-prolonging activities of Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetracaine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tetrodotoxin.
ThalidomideHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Haloperidol.
TheophyllineThe metabolism of Haloperidol can be decreased when combined with Theophylline.
ThiamylalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiopental.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Haloperidol.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Haloperidol.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Haloperidol.
ThiothixeneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Thiothixene.
TiagabineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiagabine.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Haloperidol.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Haloperidol.
TiclopidineThe metabolism of Haloperidol can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tiletamine.
TimololThe serum concentration of Timolol can be increased when it is combined with Haloperidol.
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Haloperidol.
TipranavirThe metabolism of Tipranavir can be decreased when combined with Haloperidol.
TizanidineTizanidine may increase the QTc-prolonging activities of Haloperidol.
TizanidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tizanidine.
TocilizumabThe serum concentration of Haloperidol can be decreased when it is combined with Tocilizumab.
TolbutamideThe metabolism of Haloperidol can be decreased when combined with Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Haloperidol is combined with Tolcapone.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Haloperidol.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Haloperidol.
TolterodineTolterodine may increase the QTc-prolonging activities of Haloperidol.
TolterodineThe metabolism of Tolterodine can be decreased when combined with Haloperidol.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Haloperidol.
TopiramateThe risk or severity of adverse effects can be increased when Haloperidol is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Haloperidol.
ToremifeneHaloperidol may increase the QTc-prolonging activities of Toremifene.
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Haloperidol.
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Haloperidol.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Haloperidol.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Haloperidol.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Haloperidol.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Haloperidol.
TrazodoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trazodone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Haloperidol.
TriazolamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triazolam.
TrifluoperazineThe serum concentration of Haloperidol can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Haloperidol can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triflupromazine.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Haloperidol.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Haloperidol.
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Haloperidol.
TriprolidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Triprolidine.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Haloperidol.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Haloperidol.
TroleandomycinThe serum concentration of Haloperidol can be increased when it is combined with Troleandomycin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Haloperidol.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Haloperidol.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Haloperidol.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Haloperidol.
ValsartanThe metabolism of Haloperidol can be decreased when combined with Valsartan.
VandetanibHaloperidol may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Haloperidol.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Haloperidol.
VemurafenibThe serum concentration of Haloperidol can be increased when it is combined with Vemurafenib.
VemurafenibHaloperidol may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Haloperidol.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Haloperidol.
VerapamilThe metabolism of Haloperidol can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Haloperidol.
VigabatrinThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vigabatrin.
VilanterolVilanterol may increase the QTc-prolonging activities of Haloperidol.
VilazodoneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vilazodone.
VinblastineThe serum concentration of Haloperidol can be decreased when it is combined with Vinblastine.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Haloperidol.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Haloperidol.
VincristineThe serum concentration of Haloperidol can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Haloperidol can be increased when it is combined with Vinorelbine.
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Haloperidol.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Haloperidol.
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Haloperidol.
VorinostatVorinostat may increase the QTc-prolonging activities of Haloperidol.
VortioxetineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be decreased when combined with Haloperidol.
ZafirlukastThe metabolism of Haloperidol can be decreased when combined with Zafirlukast.
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Haloperidol.
ZaleplonThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zaleplon.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Haloperidol.
ZiconotideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Haloperidol.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Haloperidol.
ZimelidineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zimelidine.
ZimelidineThe serum concentration of Haloperidol can be increased when it is combined with Zimelidine.
ZiprasidoneHaloperidol may increase the QTc-prolonging activities of Ziprasidone.
ZiprasidoneThe metabolism of Haloperidol can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zolazepam.
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Haloperidol.
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Haloperidol.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Haloperidol.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Haloperidol.
ZonisamideThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Haloperidol is combined with Zotepine.
ZuclopenthixolHaloperidol may increase the QTc-prolonging activities of Zuclopenthixol.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Haloperidol.
Food Interactions
  • Take with food to reduce irritation, limit caffeine intake. Avoid alcohol.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Osinski MA, Uchic ME, Seifert T, Shaughnessy TK, Miller LN, Nakane M, Cox BF, Brioni JD, Moreland RB: Dopamine D2, but not D4, receptor agonists are emetogenic in ferrets. Pharmacol Biochem Behav. 2005 May;81(1):211-9. [PubMed:15894081 ]
  2. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore GJ, Bolognani F, Lauriello J, Perrone-Bizzozero N, Galloway MP: Long-term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology. 2006 Apr;31(4):751-6. [PubMed:16132064 ]
  3. Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, Sasaki T, Naganawa M, Chihara K, Okubo Y, Ishii K: A feasibility study of [11C]SA4503-PET for evaluating sigmal receptor occupancy by neuroleptics: the binding of haloperidol to sigma1 and dopamine D2-like receptors. Ann Nucl Med. 2006 Oct;20(8):569-73. [PubMed:17134027 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Naiker DV, Catts SV, Catts VS, Bedi KS, Bryan-Lluka LJ: Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat. Eur J Pharmacol. 2006 Jul 1;540(1-3):87-90. Epub 2006 May 11. [PubMed:16730699 ]
  6. Uchida S, Kato Y, Hirano K, Kagawa Y, Yamada S: Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine. Life Sci. 2007 Apr 3;80(17):1635-40. Epub 2007 Jan 27. [PubMed:17316700 ]
  7. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  8. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses. 2010 Apr;4(1):56-73. doi: 10.3371/CSRP.4.1.5. [PubMed:20643630 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Zinc ion binding
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. In concert with DAPK1 at extrasynaptic sites, acts as a central mediator for stroke damage. Its phosphorylation at Ser-1303 by DAPK1 enhances synaptic NMDA receptor channel activity inducing injurious Ca2+ influx through them, resulting in an ...
Gene Name:
GRIN2B
Uniprot ID:
Q13224
Molecular Weight:
166365.885 Da
References
  1. Hattori K, Uchino S, Isosaka T, Maekawa M, Iyo M, Sato T, Kohsaka S, Yagi T, Yuasa S: Fyn is required for haloperidol-induced catalepsy in mice. J Biol Chem. 2006 Mar 17;281(11):7129-35. Epub 2006 Jan 10. [PubMed:16407246 ]
  2. Zhuravliova E, Barbakadze T, Natsvlishvili N, Mikeladze DG: Haloperidol induces neurotoxicity by the NMDA receptor downstream signaling pathway, alternative from glutamate excitotoxicity. Neurochem Int. 2007 Jun;50(7-8):976-82. Epub 2006 Nov 7. [PubMed:17092607 ]
  3. Gu WH, Yang S, Shi WX, Zhen XC, Jin GZ: Effects of (-)-stepholidine on NMDA receptors: comparison with haloperidol and clozapine. Acta Pharmacol Sin. 2007 Jul;28(7):953-8. [PubMed:17588330 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  5. Steinmetz RD, Fava E, Nicotera P, Steinhilber D: A simple cell line based in vitro test system for N-methyl-D-aspartate (NMDA) receptor ligands. J Neurosci Methods. 2002 Jan 15;113(1):99-110. [PubMed:11741727 ]
  6. Sinor JD, Du S, Venneti S, Blitzblau RC, Leszkiewicz DN, Rosenberg PA, Aizenman E: NMDA and glutamate evoke excitotoxicity at distinct cellular locations in rat cortical neurons in vitro. J Neurosci. 2000 Dec 1;20(23):8831-7. [PubMed:11102491 ]
  7. Gallagher MJ, Huang H, Lynch DR: Modulation of the N-methyl-D-aspartate receptor by haloperidol: NR2B-specific interactions. J Neurochem. 1998 May;70(5):2120-8. [PubMed:9572299 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  2. Cai G, Gurdal H, Smith C, Wang HY, Friedman E: Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein. Mol Pharmacol. 1999 Nov;56(5):989-96. [PubMed:10531405 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other/unknown
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inverse agonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase. Promotes cell proliferation.
Gene Name:
DRD3
Uniprot ID:
P35462
Molecular Weight:
44224.335 Da
References
  1. Leysen JE, Janssen PM, Megens AA, Schotte A: Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994 May;55 Suppl:5-12. [PubMed:7520908 ]
  2. Tuppurainen H, Kuikka JT, Viinamaki H, Husso M, Tiihonen J: Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci. 2009 Aug;63(4):529-37. doi: 10.1111/j.1440-1819.2009.01982.x. Epub 2009 May 22. [PubMed:19496999 ]
  3. Tadori Y, Forbes RA, McQuade RD, Kikuchi T: Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur J Pharmacol. 2008 Nov 12;597(1-3):27-33. doi: 10.1016/j.ejphar.2008.09.008. Epub 2008 Sep 20. [PubMed:18831971 ]
  4. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, Meltzer HY: Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology. 2005 Dec;30(12):2283-9. [PubMed:16123775 ]
  5. Malmberg, Mikaels, Mohell N: Agonist and inverse agonist activity at the dopamine D3 receptor measured by guanosine 5'--gamma-thio-triphosphate--35S- binding. J Pharmacol Exp Ther. 1998 Apr;285(1):119-26. [PubMed:9536001 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Tateishi T, Watanabe M, Kumai T, Tanaka M, Moriya H, Yamaguchi S, Satoh T, Kobayashi S: CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci. 2000 Nov 3;67(24):2913-20. [PubMed:11133003 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Micallef J, Fakra E, Blin O: [Use of antidepressant drugs in schizophrenic patients with depression]. Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. [PubMed:16910628 ]
  2. Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit. 2000 Feb;22(1):118-21. [PubMed:10688273 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Kalgutkar AS, Taylor TJ, Venkatakrishnan K, Isin EM: Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab Dispos. 2003 Mar;31(3):243-9. [PubMed:12584149 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Prostaglandin-e2 9-reductase activity
Specific Function:
NADPH-dependent reductase with broad substrate specificity. Catalyzes the reduction of a wide variety of carbonyl compounds including quinones, prostaglandins, menadione, plus various xenobiotics. Catalyzes the reduction of the antitumor anthracyclines doxorubicin and daunorubicin to the cardiotoxic compounds doxorubicinol and daunorubicinol. Can convert prostaglandin E2 to prostaglandin F2-alp...
Gene Name:
CBR1
Uniprot ID:
P16152
Molecular Weight:
30374.73 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  3. Boulton DW, DeVane CL, Liston HL, Markowitz JS: In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002 May 31;71(2):163-9. [PubMed:12031686 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23